230 related articles for article (PubMed ID: 19716829)
1. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches.
Li N; Liu JY; Timofeyev V; Qiu H; Hwang SH; Tuteja D; Lu L; Yang J; Mochida H; Low R; Hammock BD; Chiamvimonvat N
J Mol Cell Cardiol; 2009 Dec; 47(6):835-45. PubMed ID: 19716829
[TBL] [Abstract][Full Text] [Related]
2. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors.
Xu D; Li N; He Y; Timofeyev V; Lu L; Tsai HJ; Kim IH; Tuteja D; Mateo RK; Singapuri A; Davis BB; Low R; Hammock BD; Chiamvimonvat N
Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18733-8. PubMed ID: 17130447
[TBL] [Abstract][Full Text] [Related]
3. Soluble epoxide hydrolase inhibitors and heart failure.
Qiu H; Li N; Liu JY; Harris TR; Hammock BD; Chiamvimonvat N
Cardiovasc Ther; 2011 Apr; 29(2):99-111. PubMed ID: 20433684
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse model.
Chen L; Fan C; Zhang Y; Bakri M; Dong H; Morisseau C; Maddipati KR; Luo P; Wang CY; Hammock BD; Wang MH
Prostaglandins Other Lipid Mediat; 2013; 104-105():42-8. PubMed ID: 23247129
[TBL] [Abstract][Full Text] [Related]
5. Soluble epoxide hydrolase inhibitors, t-AUCB, downregulated miR-133 in a mouse model of myocardial infarction.
Gui Y; Li D; Chen J; Wang Y; Hu J; Liao C; Deng L; Xiang Q; Yang T; Du X; Zhang S; Xu D
Lipids Health Dis; 2018 May; 17(1):129. PubMed ID: 29843720
[TBL] [Abstract][Full Text] [Related]
6. Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.
Roche C; Besnier M; Cassel R; Harouki N; Coquerel D; Guerrot D; Nicol L; Loizon E; Remy-Jouet I; Morisseau C; Mulder P; Ouvrard-Pascaud A; Madec AM; Richard V; Bellien J
Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1020-9. PubMed ID: 25724490
[TBL] [Abstract][Full Text] [Related]
7. A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARγ to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction.
Xu DY; Davis BB; Wang ZH; Zhao SP; Wasti B; Liu ZL; Li N; Morisseau C; Chiamvimonvat N; Hammock BD
Int J Cardiol; 2013 Aug; 167(4):1298-304. PubMed ID: 22525341
[TBL] [Abstract][Full Text] [Related]
8. Soluble epoxide hydrolase inhibitors and cardiovascular diseases.
Wang ZH; Davis BB; Jiang DQ; Zhao TT; Xu DY
Curr Vasc Pharmacol; 2013 Jan; 11(1):105-11. PubMed ID: 22303912
[TBL] [Abstract][Full Text] [Related]
9. Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis.
Sirish P; Li N; Liu JY; Lee KS; Hwang SH; Qiu H; Zhao C; Ma SM; López JE; Hammock BD; Chiamvimonvat N
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):5618-23. PubMed ID: 23493561
[TBL] [Abstract][Full Text] [Related]
10. Reduced coronary reactive hyperemia in mice was reversed by the soluble epoxide hydrolase inhibitor (t-AUCB): Role of adenosine A
Hanif A; Edin ML; Zeldin DC; Morisseau C; Falck JR; Ledent C; Tilley SL; Nayeem MA
Prostaglandins Other Lipid Mediat; 2017 Jul; 131():83-95. PubMed ID: 28890385
[TBL] [Abstract][Full Text] [Related]
11. Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure.
Merabet N; Bellien J; Glevarec E; Nicol L; Lucas D; Remy-Jouet I; Bounoure F; Dreano Y; Wecker D; Thuillez C; Mulder P
J Mol Cell Cardiol; 2012 Mar; 52(3):660-6. PubMed ID: 22155238
[TBL] [Abstract][Full Text] [Related]
12. Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice.
Zhang W; Yang AL; Liao J; Li H; Dong H; Chung YT; Bai H; Matkowskyj KA; Hammock BD; Yang GY
Dig Dis Sci; 2012 Oct; 57(10):2580-91. PubMed ID: 22588244
[TBL] [Abstract][Full Text] [Related]
13. Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.
Ni GH; Chen JF; Chen XP; Yang TL
Pharmazie; 2011 Mar; 66(3):153-7. PubMed ID: 21553642
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophoric modeling and atom-based 3D-QSAR of novel 1-aryl-3-(1-acylpiperidin-4-yl) urea as human soluble epoxide hydrolase inhibitors (sEHIs).
Das N; Dhanawat M; Kulshrestha A; Shrivastava SK
Med Chem; 2011 Nov; 7(6):581-92. PubMed ID: 22313298
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model.
Liu JY; Yang J; Inceoglu B; Qiu H; Ulu A; Hwang SH; Chiamvimonvat N; Hammock BD
Biochem Pharmacol; 2010 Mar; 79(6):880-7. PubMed ID: 19896470
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension.
Neckář J; Kopkan L; Husková Z; Kolář F; Papoušek F; Kramer HJ; Hwang SH; Hammock BD; Imig JD; Malý J; Netuka I; Ošťádal B; Červenka L
Clin Sci (Lond); 2012 Jun; 122(11):513-25. PubMed ID: 22324471
[TBL] [Abstract][Full Text] [Related]
17. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
Motoki A; Merkel MJ; Packwood WH; Cao Z; Liu L; Iliff J; Alkayed NJ; Van Winkle DM
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2128-34. PubMed ID: 18835921
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of soluble epoxide hydrolase minimize ischemia-reperfusion-induced cardiac damage in normal, hypertensive, and diabetic rats.
Islam O; Patil P; Goswami SK; Razdan R; Inamdar MN; Rizwan M; Mathew J; Inceoglu B; Stephen Lee KS; Hwang SH; Hammock BD
Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28296232
[TBL] [Abstract][Full Text] [Related]
19. Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis.
Li L; Li N; Pang W; Zhang X; Hammock BD; Ai D; Zhu Y
PLoS One; 2014; 9(4):e94092. PubMed ID: 24718617
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula.
Červenka L; Melenovský V; Husková Z; Sporková A; Bürgelová M; Škaroupková P; Hwang SH; Hammock BD; Imig JD; Sadowski J
Physiol Res; 2015; 64(6):857-73. PubMed ID: 26047375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
